• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Selumetinib

Selumetinib

Product ID S1846
Cas No. 606143-52-6
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $58.50 In stock
10 mg $97.30 In stock
50 mg $227.10 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Selumetinib is an orally bioavailable noncompetitive inhibitor of MEK1/2; it primarily displays immunosuppressive and anticancer chemotherapeutic activities. In cellular and animal models of cancer, selumetinib downregulates MAPK activation and mTOR phosphorylation and upregulates caspases 3 and 7, resulting in caspase-mediated apoptosis and inhibition of tumor growth. In an animal model of graft versus host disease (GVHD), selumetinib inhibits alloreactivity through inhibition of naïve and less-differentiated T cells. Additionally, this compound decreased serum creatine phosphokinase and aspartate aminotransferase to inhibit skeletal muscle pathology and increase muscle function in an animal model of muscular dystrophy.

Product Info

Cas No.

606143-52-6

Purity

≥99%

Formula

C17H15BrClFN4O3

Formula Wt.

457.68

Chemical Name

Selumetinib

IUPAC Name

6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3- methylbenzimidazole-5-carboxamide

Synonym

AZD6244, ARRY 142886; 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

S1846 MSDS PDF

Info Sheet

S1846 Info Sheet PDF

Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Paolo M, Assunta S, Antonio R, et al. Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC. Rev Recent Clin Trials. 2013 Jun;8(2):93-100. PMID: 24063423.

Muchir A, Kim YJ, Reilly SA, et al. Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation. Skelet Muscle. 2013 Jul 1;3(1):17. PMID: 23815988.

Shindo T, Kim TK, Benjamin CL, et al. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood. 2013 Jun 6;121(23):4617-26. PMID: 23575444.

Sabnis GJ, Kazi A, Golubeva O, et al. Effect of selumetinib on the growth of anastrozole-resistant tumors. Breast Cancer Res Treat. 2013 Apr;138(3):699-708. PMID: 23508762.

Huynh H, Soo KC, Chow PK, et al. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther. 2007 Jan;6(1):138-46. PMID: 17237274.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • M568264

    Mogroside IIe

    Triterpenoid

    ≥98%
  • B1992

    Bexarotene

    RXR agonist.

    ≥98%
  • K1653

    Kendomycin

    Macrolide; ET antagonist, proteasome inhibitor....

    ≥98%
  • C4656

    Clopidol

    Coccidiostat.

    ≥98%
  • F8147

    Fulvestrant

    Induces ER degradation.

    ≥98%
  • F4584

    Fluphenazine Hydrochloride

    Piperazine; FIASMA, D2 antagonist, hERG K+ chan...

    ≥97%
  • R5212

    RN-486

    Btk inhibitor.

    ≥98%
  • R8122

    Rufloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • K0276

    Katacalcin

    Peptide found in crustaceans; PKA activator.

    ≥95%
  • A851322

    Avibactam Sodium

    Diazabicyclooctane β-lactamase inhibitor.

    ≥98%
  • P6956

    Prostaglandin E1

    Endogenous prostaglandin, vasodilator.

    ≥98%
  • D3352

    Dinaciclib

    BRD binding agent, CDK1/2/5/9 inhibitor.

    ≥99%
  • T1002

    2-Debenzoyl Paclitaxel-2-(2-Methyl-2-Butenoate)

    Synthesis intermediate

    ≥95%
  • A965121

    AZD-5438

    Inhibitor of CDK.

    ≥98%
  • T0095

    Baccatin III

    Diterpene found in Taxus, used to synthesize ta...

    ≥98%
  • F4483

    Flufenamic Acid

    NSAID; TREK1 K+ potentiator, voltage-gated Na+ ...

    ≥97%
  • D019601

    Dapagliflozin

    SGLT2 inhibitor

    ≥98%
  • P0344

    Palbociclib Isethionate

    CDK4/6 inhibitor.

    ≥98%
  • O9322

    Oxfendazole

    Benzimidazole; microtubule polymerization inhib...

    ≥98%
  • S0134

    Saikosaponin D

    Triterpene saponin found in Bupleurum.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only